Downstream Polish And Viral Clearance

11. Multi-Specific Antibody Development: What Challenges The Need For Speed? 8/9/2023

    In this segment of the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline, Bayer’s Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., addresses why the industry is pursuing faster, more cost-effective multi-specific antibody development and some of the major challenges standing in the way of efficiency.